Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy

Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy

Copyright 2020, SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 51(2020), 8 vom: 01. Aug., Seite 448-455
1. Verfasser: Statler, Brittney (VerfasserIn)
Weitere Verfasser: Conti, Thais F, Conti, Felipe F, Silva, Fabiana Q, Rachitskaya, Aleksandra, Yuan, Alex, Schachat, Andrew, Kaiser, Peter K, Singh, Rishi P, Babiuch, Amy
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Angiogenesis Inhibitors Recombinant Fusion Proteins Vascular Endothelial Growth Factor A aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1
LEADER 01000caa a22002652c 4500
001 NLM313920869
003 DE-627
005 20250227200329.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20200804-05  |2 doi 
028 5 2 |a pubmed25n1046.xml 
035 |a (DE-627)NLM313920869 
035 |a (NLM)32818277 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Statler, Brittney  |e verfasserin  |4 aut 
245 1 0 |a Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 21.07.2021 
500 |a Date Revised 21.07.2021 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 2020, SLACK Incorporated. 
520 |a BACKGROUND AND OBJECTIVE: Evaluate capillary perfusion density (CPD) in patients with diabetic macular edema (DME) undergoing fixed intravit-real aflibercept injections (IAI) through 24 months 
520 |a PATIENTS AND METHODS: Prospective, interventional, single-arm study enrolling 20 patients with persistent DME. Patients received IAI every 4 weeks until DME resolution followed by extension to every 8 weeks. Optical coherence tomography angiography was obtained at baseline, 6, 12, and 24 months 
520 |a RESULTS: Sixteen of 20 eyes completed the study. Baseline mean central subfield thickness was 420 µm, which improved to 251 µm (P < .001). The mean best-corrected visual acuity (BCVA) improved by 5.5 letters (P = .042). The whole superficial CPD decreased by 5.3% (P = .001) and the deep CPD decreased by 4.4% (P = .009). Better BCVA correlated with less CPD loss within the superficial parafovea (r = +0.66 [0.23, 0.88]; P = .006) and whole (r = +0.60 [0.12, 0.85]; P = .017) areas 
520 |a CONCLUSION: Superficial and deep CPD decreased despite fixed IAI through 24 months. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:448-455.] 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Angiogenesis Inhibitors  |2 NLM 
650 7 |a Recombinant Fusion Proteins  |2 NLM 
650 7 |a Vascular Endothelial Growth Factor A  |2 NLM 
650 7 |a aflibercept  |2 NLM 
650 7 |a 15C2VL427D  |2 NLM 
650 7 |a Receptors, Vascular Endothelial Growth Factor  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
700 1 |a Conti, Thais F  |e verfasserin  |4 aut 
700 1 |a Conti, Felipe F  |e verfasserin  |4 aut 
700 1 |a Silva, Fabiana Q  |e verfasserin  |4 aut 
700 1 |a Rachitskaya, Aleksandra  |e verfasserin  |4 aut 
700 1 |a Yuan, Alex  |e verfasserin  |4 aut 
700 1 |a Schachat, Andrew  |e verfasserin  |4 aut 
700 1 |a Kaiser, Peter K  |e verfasserin  |4 aut 
700 1 |a Singh, Rishi P  |e verfasserin  |4 aut 
700 1 |a Babiuch, Amy  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 51(2020), 8 vom: 01. Aug., Seite 448-455  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnas 
773 1 8 |g volume:51  |g year:2020  |g number:8  |g day:01  |g month:08  |g pages:448-455 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20200804-05  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
951 |a AR 
952 |d 51  |j 2020  |e 8  |b 01  |c 08  |h 448-455